<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Yousif I A-Rahim, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Farrell, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sunanda V Kane, MD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Ulcerative colitis (UC) is a chronic inflammatory disease of the colon characterized by bloody diarrhea. Biologic agents, including tumor necrosis factor-alpha inhibitors (eg, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>) and anti-integrin antibodies (<a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a>), and small molecules (eg, <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a>) are used for treating patients with moderately-to-severely active UC.</p><p>Dosing, monitoring, and adverse effects of biologic agents and small molecules for the treatment of UC in adults will be reviewed here. Selecting a specific biologic agent or a small molecule is influenced by the indication, patient preference, patient medical history, clinician preference, availability in individual countries, and insurance coverage/cost. Medical management of UC is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4068.html" rel="external">"Management of the hospitalized adult patient with severe ulcerative colitis"</a>.)</p><p></p><p>An overview of thiopurine therapy (<a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">mercaptopurine</a>) in inflammatory bowel disease (IBD) is discussed separately. (See  <a class="medical medical_review" href="/d/html/4056.html" rel="external">"Overview of azathioprine and mercaptopurine use in inflammatory bowel disease"</a>.)</p><p>An overview of <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> therapy for IBD is discussed separately. (See  <a class="medical medical_review" href="/d/html/4061.html" rel="external">"Overview of budesonide therapy for adults with inflammatory bowel disease"</a>.)</p><p>Adjustments to medication regimens for patients with IBD and suspected or known coronavirus disease 19 (COVID-19) are discussed separately. (See  <a class="medical medical_review" href="/d/html/127965.html" rel="external">"COVID-19: Issues related to gastrointestinal disease in adults", section on 'Inflammatory bowel disease'</a>.)</p><p class="headingAnchor" id="H3158016022"><span class="h1">TUMOR NECROSIS FACTOR INHIBITORS</span></p><p class="headingAnchor" id="H3749051024"><span class="h2">Pharmacology and use</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, and <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a> are monoclonal antibodies directed against anti-tumor necrosis factor (TNF)-alpha. The efficacy of TNF agents for treating Crohn disease provided the rationale for clinical trials of infliximab (and other anti-TNF agents) in patients with UC, a disorder in which TNF also has an important role. TNF-alpha is expressed at high levels in the colonic mucosa of patients with UC [<a href="#rid1">1</a>].</p><p>The basis for using these agents is that TNF-alpha has several biologic activities that may be directly related to the pathogenesis of IBD and to the dysregulation of the immune system that occurs in patients with IBD. (See  <a class="medical medical_review" href="/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'Anticytokine approaches'</a> and  <a class="medical medical_review" href="/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a> –<strong> </strong>Infliximab is a chimeric monoclonal antibody comprised of 75 percent human and 25 percent murine sequences, which has a high specificity for and affinity to TNF-alpha. Infliximab neutralizes the biologic activity of TNF-alpha by inhibiting binding to its receptors. Infliximab is used by most clinicians in combination with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">Adalimumab</a> –<strong> </strong>Adalimumab is a recombinant, fully human monoclonal antibody that binds to TNF-alpha, thereby interfering with binding to TNF-alpha receptor sites and subsequent cytokine-driven inflammatory processes. The humanized construction of adalimumab is presumed to lower the risk of forming anti-drug antibodies compared with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>. (See  <a class="medical medical_review" href="/d/html/7974.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases", section on 'Adalimumab-induced human anti-human antibodies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">Golimumab</a> – Golimumab is a fully human monoclonal antibody that neutralizes TNF-alpha activity. Golimumab has a longer half-life than <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>. (See <a class="local">'Golimumab'</a> below and  <a class="medical medical_review" href="/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'Golimumab'</a>.)</p><p></p><p class="headingAnchor" id="H296340496"><span class="h2">Pretreatment screening</span><span class="headingEndMark"> — </span>Prior to starting a biologic agent, we review each patient's vaccination and exposure history. Ideally, this review should be performed before the start of immunosuppressive therapy, when the likelihood of developing a protective immune response to any needed vaccine is highest and when live vaccines can be given safely. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Approach to vaccination'</a>.)</p><p>Pretreatment screening includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis B surface antigen (HBsAg), hepatitis B surface antibody, and hepatitis B core antibody.</p><p></p><p class="bulletIndent1">Patients with serologic evidence of hepatitis B virus (HBV) infection (HBsAg-positive or anti-HBc-positive) are at risk for HBV reactivation if they receive immunosuppressive therapy. Prevention, diagnosis, and treatment of HBV reactivation are discussed separately. (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis C virus (HCV) antibody. For patients with HCV antibodies, we obtain HCV RNA. If HCV RNA is detected, we refer the patient to a hepatologist for consideration of treatment. (See  <a class="medical medical_review" href="/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection"</a>.)</p><p></p><p class="bulletIndent1">However, chronic HCV infection is not a contraindication for immunosuppressive therapy [<a href="#rid2">2,3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interferon-gamma release assay such as QuantiFERON-TB Gold In-Tube assay (preferred) or <a class="drug drug_general" data-topicid="10029" href="/d/drug information/10029.html" rel="external">tuberculin skin test</a>.</p><p></p><p class="bulletIndent1">If the screening test for latent tuberculosis is positive, a chest radiograph is obtained and the patient is referred to an infectious disease specialist for further evaluation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors", section on 'Screening'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/15352.html" rel="external">"Use of interferon-gamma release assays for diagnosis of tuberculosis infection (tuberculosis screening) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Documenting immunity to varicella (eg, varicella zoster virus IgG, clinician diagnosis of disease). (See  <a class="medical medical_review" href="/d/html/8329.html" rel="external">"Diagnosis of varicella-zoster virus infection", section on 'Serologic testing'</a>.)</p><p></p><p class="bulletIndent1">For patients with evidence of immunity who are ≥19 years old, we assess the need for and timing of zoster (shingles) vaccination, and this is discussed separately. (See  <a class="medical medical_review" href="/d/html/103773.html" rel="external">"Immunizations in autoimmune inflammatory rheumatic disease in adults", section on 'Zoster vaccines'</a>.)</p><p></p><p class="bulletIndent1">For patients without evidence of immunity, we assess the need for varicella vaccination based on patient age and risk status, and this is discussed separately. (See  <a class="medical medical_review" href="/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Immunizations'</a> and  <a class="medical medical_review" href="/d/html/103773.html" rel="external">"Immunizations in autoimmune inflammatory rheumatic disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serologic testing for Epstein-Barr virus (EBV) and cytomegalovirus (CMV). We obtain anti-EBV and anti-CMV antibodies to assess for evidence of prior infection and thus the patient's risk of reactivation [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/8283.html" rel="external">"Clinical manifestations and treatment of Epstein-Barr virus infection"</a> and  <a class="medical medical_review" href="/d/html/8291.html" rel="external">"Overview of diagnostic tests for cytomegalovirus infection"</a>.)</p><p></p><p class="headingAnchor" id="H2733335232"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>Contraindications to the use of anti-TNF therapies (briefly summarized) include the following. (See  <a class="medical medical_review" href="/d/html/7790.html" rel="external">"Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'Use of TNF inhibitors'</a>.):</p><p class="bulletIndent1"><span class="glyph">●</span>Active, untreated infection</p><p class="bulletIndent1"><span class="glyph">●</span>Latent (untreated) tuberculosis</p><p class="bulletIndent1"><span class="glyph">●</span>Demyelinating disease (eg, multiple sclerosis, optic neuritis)</p><p class="bulletIndent1"><span class="glyph">●</span>Uncontrolled heart failure</p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy </p><p></p><p>The safety of anti-TNF therapies and risk of recurrent malignancy in patients with a history of malignancy is less well established than in patients without such a history; the available data are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy"</a>.)</p><p class="headingAnchor" id="H3968998270"><span class="h2">Dosing and administration</span><span class="headingEndMark"> — </span>This section describes induction and maintenance dosing for <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, and <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a>. In addition, options for dose escalation are included for patients with loss of response while on maintenance therapy. The approach to the patient with UC who is not responding to induction anti-TNF therapy is discussed separately. (See  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults"</a> and  <a class="medical medical_review" href="/d/html/4068.html" rel="external">"Management of the hospitalized adult patient with severe ulcerative colitis"</a>.)</p><p>Decisions regarding dose adjustments for patients on maintenance therapy who lose response can be guided by therapeutic drug monitoring  (<a class="graphic graphic_table graphicRef117391" href="/d/graphic/117391.html" rel="external">table 1</a>). (See <a class="local">'Therapeutic drug monitoring'</a> below.)</p><p class="headingAnchor" id="H1174533162"><span class="h3">Infliximab</span><span class="headingEndMark"> — </span>The induction dose of <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> for treatment of patients with moderately to severely active UC is 5 mg/kg intravenously at zero-, two-, and six- weeks [<a href="#rid4">4,5</a>].</p><p>Patients who achieve an adequate response (based on clinical, endoscopic, and laboratory findings) to initial therapy will require repeat infusions of 5 mg/kg, usually every eight weeks, to maintain remission.</p><p>Patients who have a disease flare while on maintenance dosing can be managed by escalating the dose [<a href="#rid6">6</a>]. This can be accomplished by either decreasing the dosing interval (eg, from eight weeks to six weeks) or by increasing the dose (eg, from 5 mg/kg to 10 mg/kg). The maximal dose of <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> is 10 mg/kg every four weeks.</p><p class="headingAnchor" id="H3465597089"><span class="h3">Adalimumab</span><span class="headingEndMark"> — </span>Induction therapy with <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> is given subcutaneously with the following regimen [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Week zero, initial dose – 160 mg, given over one or two days</p><p class="bulletIndent1"><span class="glyph">●</span>Week two – 80 mg once</p><p class="bulletIndent1"><span class="glyph">●</span>Week four and thereafter – 40 mg every other week (maintenance dose)</p><p></p><p>We suggest the same induction regimen for patients who are being switched to <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> from another anti-TNF agent.</p><p>For patients who have a disease flare while on maintenance dosing, the dosing interval can be shortened to every week [<a href="#rid8">8,9</a>].</p><p class="headingAnchor" id="H220714301"><span class="h3">Golimumab</span><span class="headingEndMark"> — </span>The recommended induction dose for <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a> is 200 mg subcutaneously at week zero, then 100 mg at week two, followed by weight-based maintenance therapy [<a href="#rid10">10,11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with actual body weight ≥80 kg – 100 mg every four weeks</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with actual body weight &lt;80 kg – 50 mg every four weeks</p><p></p><p>For patients who have loss of response while on maintenance dosing and who are candidates for dose escalation, options include increasing the maintenance dose to 100 mg every four weeks, irrespective of body weight [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H20827636"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>In addition to clinical observation, monitoring the response to anti-TNF agents may include therapeutic drug monitoring (checking drug trough levels, anti-drug antibodies) and biomarker levels (C-reactive protein, fecal calprotectin). Time intervals for follow-up colonoscopy to assess for endoscopic remission are discussed separately. (See  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults"</a>.)</p><p class="headingAnchor" id="H1710291240"><span class="h3">Therapeutic drug monitoring</span><span class="headingEndMark"> — </span>Therapeutic drug monitoring involves measuring serum drug trough concentrations and anti-drug antibodies to optimize the use of anti-TNF agents for patients with IBD. Selecting patients for therapeutic drug monitoring and modifying anti-TNF therapy based on monitoring is discussed separately. (See  <a class="medical medical_review" href="/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors", section on 'Therapeutic drug monitoring'</a>.)</p><p>The suggested target drug trough concentrations are primarily based on cross-sectional studies of patients on maintenance therapy [<a href="#rid13">13,14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a>: ≥5 mcg/mL</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">Adalimumab</a>: ≥7.5 mcg/mL</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">Golimumab</a>: &gt;1 mg/L [<a href="#rid15">15</a>]</p><p></p><p class="headingAnchor" id="H1104455788"><span class="h3">Biomarkers of inflammation</span><span class="headingEndMark"> — </span>In addition to therapeutic drug monitoring, obtaining biomarkers of inflammation (eg, fecal calprotectin or lactoferrin, C-reactive protein [CRP]) can help guide therapy to achieve endoscopic and clinical remission in patients with UC [<a href="#rid16">16,17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stool inflammatory markers</strong> – Fecal calprotectin can be used to monitor response to anti-TNF therapy in patients with UC, because fecal calprotectin levels correlate with endoscopic disease activity [<a href="#rid18">18-21</a>]. Fecal calprotectin levels are also more accurate than serum inflammatory markers (eg, CRP) for detecting active disease [<a href="#rid22">22</a>]. Calprotectin is a calcium binding protein complex, found in abundance in neutrophilic granulocytes, and fecal calprotectin levels are increased in patients with mucosal inflammation [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/2591.html" rel="external">"Approach to the adult with chronic diarrhea in resource-abundant settings", section on 'General laboratory tests'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CRP</strong> – A high baseline CRP level that normalizes with treatment has been associated with a higher chance of having a response to <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid23">23,24</a>].</p><p></p><p class="headingAnchor" id="H202297312"><span class="h2">Adverse events</span><span class="headingEndMark"> — </span>The TNF-alpha inhibitors have multiple potential adverse events that are listed below and discussed in more detail separately [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.):</p><p class="bulletIndent1"><span class="glyph">●</span>Infection. (See  <a class="medical medical_review" href="/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a> and  <a class="medical medical_review" href="/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"</a>.).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy. (See  <a class="medical medical_review" href="/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy"</a>.).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Induction of autoimmunity. (See  <a class="medical medical_review" href="/d/html/7974.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Demyelinating disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Worsening or new onset heart failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Injection site reactions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neutropenia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infusion reactions  (<a class="graphic graphic_algorithm graphicRef85655" href="/d/graphic/85655.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects", section on 'Infusion reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cutaneous reactions, including psoriasiform lesions.</p><p></p><p>The risk of combination therapy (ie, anti-TNF agent plus an immunomodulator [eg, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>]) in patients with IBD is discussed separately. (See  <a class="medical medical_review" href="/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors", section on 'Risks with combination therapy'</a>.)</p><p class="headingAnchor" id="H4102274063"><span class="h1">ANTI-INTEGRIN ANTIBODIES</span></p><p class="headingAnchor" id="H1419600091"><span class="h2">Pharmacology and use</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">Vedolizumab</a> is a recombinant humanized, monoclonal antibody, developed as a gut-selective anti-integrin specifically targeting alpha-4-beta-7 integrin in the gastrointestinal tract [<a href="#rid26">26</a>]. Integrins are proteins involved in regulating cellular movement including migration of leukocytes to the gut. Vedolizumab is not typically associated with systemic immunosuppression because it interferes with lymphocyte trafficking limited to the gastrointestinal tract.</p><p><a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">Vedolizumab</a> is used for the treatment of moderately to severely active UC.</p><p class="headingAnchor" id="H4078760203"><span class="h2">Pretreatment screening</span><span class="headingEndMark"> — </span>Prior to starting a biologic agent, we review each patient's vaccination and exposure history, as discussed above. (See <a class="local">'Pretreatment screening'</a> above.)</p><p class="headingAnchor" id="H3133188782"><span class="h2">Dosing and administration</span><span class="headingEndMark"> — </span>The induction dose of <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a> for treatment of patients with moderately to severely active UC is 300 mg intravenously at zero-, two-, and six- weeks then every eight weeks thereafter [<a href="#rid27">27,28</a>].</p><p>Patients who achieve an adequate response (based on clinical and endoscopic findings) to initial therapy will require repeat infusions of 300 mg, usually every eight weeks, to maintain remission. For patients who flare while on maintenance therapy, the dose can be escalated by decreasing the <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a> dosing interval (ie, 300 mg intravenously every four weeks) [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H4228161829"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>In addition to clinical observation, monitoring the response to <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a> may include checking levels of biomarkers (C-reactive protein, fecal calprotectin). Time intervals for follow-up colonoscopy to assess for endoscopic remission are discussed separately. (See <a class="local">'Biomarkers of inflammation'</a> above and  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults"</a>.)</p><p class="headingAnchor" id="H216404488"><span class="h2">Adverse events</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">Vedolizumab</a> use is associated with low incidence of serious infection or infusion-related reactions, although mild nasopharyngitis is a common side effect [<a href="#rid27">27,30</a>]. In an analysis of safety data from four trials including 1256 patients with UC, treatment with vedolizumab was not associated with a higher rate of serious infections compared with placebo (2.7 per 100 person-years [95% CI 1.9-3.4] versus 5.0 per 100 person-years [95% CI 0.1-10.0]) [<a href="#rid31">31</a>]. In an analysis of six studies including 2830 patients with IBD, the rate of infusion-related reactions was ≤5 percent, and most were mild or moderate in intensity and rarely resulted in discontinuation of the drug [<a href="#rid31">31</a>].</p><p>Data suggest that for patients with UC, the risk of serious infection is lower with <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a> compared with other biologic agents. In a study including three population-based cohorts with mean follow-up of 1.1 years, patients with UC had lower risk of serious infection with vedolizumab compared with anti-TNF agents (incidence rate: 17.6 versus 20.4 per 1000 person-years; hazard ratio [HR] 0.68, 95% CI 0.50-0.93) [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H2348745434"><span class="h1">SMALL MOLECULES</span></p><p class="headingAnchor" id="H971093506"><span class="h2">Janus kinase (JAK) inhibitors</span></p><p class="headingAnchor" id="H418375372"><span class="h3">Pharmacology and use</span><span class="headingEndMark"> — </span>The oral JAK inhibitors that are available for treating moderate to severe UC include <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> and <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a>. JAK inhibitors decrease signaling by a number of cytokine and growth factor receptors [<a href="#rid32">32,33</a>].</p><p class="headingAnchor" id="H1037548192"><span class="h3">Pretreatment screening</span><span class="headingEndMark"> — </span>Prior to starting a JAK inhibitor, we review each patient's vaccination and exposure history (as discussed above), and we check total cholesterol and high density lipoprotein levels because <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> is associated with increased cholesterol levels [<a href="#rid34">34-36</a>]. (See <a class="local">'Pretreatment screening'</a> above.)</p><p>Pretreatment screening includes documenting immunity to varicella (eg, varicella zoster virus IgG, clinician diagnosis of disease). (See  <a class="medical medical_review" href="/d/html/8329.html" rel="external">"Diagnosis of varicella-zoster virus infection", section on 'Serologic testing'</a>.)</p><p>For patients with evidence of immunity who are ≥19 years old, we assess the need for and timing of zoster (shingles) vaccination, because <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> is associated with higher rates of herpes zoster infection [<a href="#rid37">37,38</a>]. These issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/103773.html" rel="external">"Immunizations in autoimmune inflammatory rheumatic disease in adults", section on 'Zoster vaccines'</a> and <a class="local">'Adverse events'</a> below.)</p><p class="headingAnchor" id="H3413721980"><span class="h3">Contraindications</span><span class="headingEndMark"> — </span>We do not use JAK inhibitors in patients with active serious infections (eg, tuberculosis) or severe liver impairment. In addition, we do not use <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> in patients with a history of thromboembolic disease (eg, history of pulmonary embolism, deep venous thrombosis) because of concern for increased risk of thromboembolic events and mortality in patients with rheumatoid arthritis treated with tofacitinib [<a href="#rid39">39</a>]. (See <a class="local">'Dosing and administration'</a> below and  <a class="medical medical_review" href="/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Tofacitinib'</a>.)</p><p>However, preliminary data in patients with immune-mediated inflammatory diseases suggested that <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a> was not associated with an increased risk of venous thromboembolism or major cardiovascular events [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H3365308654"><span class="h3">Dosing and administration</span><span class="headingEndMark"> — </span>We use a <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> induction dose of 5 mg twice daily for eight weeks, followed by a maintenance dose of 5 mg twice daily [<a href="#rid32">32,39,41</a>]. We use an initial induction dose of 5 mg twice daily because safety data have suggested that higher doses of tofacitinib were associated with increased risk of thromboembolism and mortality in patients with rheumatoid arthritis [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy", section on 'Tofacitinib'</a>.)</p><p>For patients with active UC who do not achieve remission with <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> 5 mg twice daily and who are at low risk for thromboembolism or cardiovascular disease, tofacitinib can be increased to 10 mg twice daily for a maximum of 16 weeks before decreasing the dose to 5 mg twice daily. (See <a class="local">'Contraindications'</a> above.)</p><p>Risk factors for thrombosis or cardiovascular events include history of inherited hypercoagulable disorder, thromboembolism, cardiovascular disease, hyperlipidemia, or malignancy; use of combined estrogen-progestin oral contraceptives or hormone replacement therapy; or patients undergoing major surgery. (See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a> and  <a class="medical medical_review" href="/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a> and  <a class="medical medical_review" href="/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"</a>.)</p><p>We use an <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a> induction dose of 45 mg daily for eight weeks, followed by a maintenance dose of 15 mg once daily [<a href="#rid42">42,43</a>]. For selected patients (eg, those who required 16 weeks of induction therapy or those who do not maintain remission with 15 mg once daily), a maintenance dose of 30 mg once daily may be appropriate. </p><p class="headingAnchor" id="H3437150903"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>Obtaining biomarkers of inflammation including fecal calprotectin and C-reactive protein can help guide therapy to achieve endoscopic and clinical remission in patients with UC [<a href="#rid16">16</a>]. Time intervals for follow-up colonoscopy to assess for endoscopic remission and monitoring lipid levels are discussed separately. (See  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Janus kinase (JAK) inhibitors'</a> and <a class="local">'Biomarkers of inflammation'</a> above.)</p><p class="headingAnchor" id="H1619417979"><span class="h3">Adverse events</span><span class="headingEndMark"> — </span>The relative safety of JAK inhibitors has generally appeared similar to that of biologic agents used for treating UC; however, additional concerns that require attention include risk of herpes zoster infection and thromboembolism [<a href="#rid37">37,38,44,45</a>]. (See  <a class="medical medical_review" href="/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Tofacitinib'</a> and <a class="local">'Contraindications'</a> above.)</p><p><a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">Tofacitinib</a> is associated with higher rates of herpes zoster infection, particularly for patients receiving higher maintenance doses [<a href="#rid37">37,38</a>]. In a study including 592 patients with UC, the incidence rate of herpes zoster was higher for patients on maintenance therapy with tofacitinib 10 mg twice daily versus placebo (6.6 per 100 person-years [95% CI 3.2-12.2] versus 1 per 100 person-years [95% CI 0.0-5.4]) [<a href="#rid37">37</a>]. However, the rate of herpes zoster was not significantly different for patients on tofacitinib 5 mg twice daily versus placebo. (See <a class="local">'Pretreatment screening'</a> above.)</p><p class="headingAnchor" id="H2052414523"><span class="h2">Sphingosine 1-phosphate (S1P) receptor modulators</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="127521" href="/d/drug information/127521.html" rel="external">Ozanimod</a> is an oral sphingosine-1-phosphate (S1P) receptor modulator for treating adults with moderate to severe UC. (See  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults"</a> and  <a class="medical medical_review" href="/d/html/129091.html" rel="external">"Overview of disease-modifying therapies for multiple sclerosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment evaluation</strong> – Prior to initiating <a class="drug drug_general" data-topicid="127521" href="/d/drug information/127521.html" rel="external">ozanimod</a>, we obtain complete blood count including lymphocyte count, liver biochemical tests, an electrocardiogram to screen for cardiac conduction abnormalities, and ophthalmic evaluation to screen for uveitis or macular edema. Patients should also be tested for antibodies to varicella zoster virus (VZV), and seronegative patients who are not yet immunosuppressed should have VZV vaccination. (See  <a class="medical medical_review" href="/d/html/103773.html" rel="external">"Immunizations in autoimmune inflammatory rheumatic disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="127521" href="/d/drug information/127521.html" rel="external">Ozanimod</a> is contraindicated in patients with myocardial infarction, unstable angina, stroke, transient ischemic attack, or heart failure in the last six months. Additional contraindications include patients with Mobitz type II second- or third-degree atrioventricular block, sick sinus syndrome, or sinoatrial block (unless the patient has a functioning pacemaker), and severe untreated sleep apnea. It is also contraindicated for patients taking a monoamine oxidase inhibitor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – <a class="drug drug_general" data-topicid="127521" href="/d/drug information/127521.html" rel="external">Ozanimod</a> is titrated slowly during the first week. We use an initial ozanimod dose of 0.23 mg daily on days 1 through 4, then 0.46 mg once daily on days 5 through 7 [<a href="#rid46">46</a>]. The maintenance dose is 0.92 once daily starting on day 8.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – In randomized trials including patients with UC, the most commonly reported adverse effects with <a class="drug drug_general" data-topicid="127521" href="/d/drug information/127521.html" rel="external">ozanimod</a> were anemia, nasopharyngitis, and headache [<a href="#rid47">47</a>]. Cardiovascular events were reported infrequently and included hypertension and bradycardia.</p><p></p><p class="headingAnchor" id="H1628589339"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span>The use of biologic agents during pregnancy and lactation is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/4083.html" rel="external">"Fertility, pregnancy, and nursing in inflammatory bowel disease", section on 'Medications during pregnancy and lactation'</a>.)</p><p class="headingAnchor" id="H1710066232"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109937.html" rel="external">"Society guideline links: Ulcerative colitis in adults"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1991.html" rel="external">"Patient education: Ulcerative colitis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2018.html" rel="external">"Patient education: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor necrosis factor (TNF) inhibitors </strong>– Tumor necrosis factor (TNF)-alpha inhibitors, including <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, and <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a>, are biologic agents used for treating patients with ulcerative colitis. The decision whether to use infliximab, adalimumab, or golimumab in patients requiring anti-TNF therapy is influenced by the indication, patient preference, and availability in individual countries. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pretreatment screening – Prior to starting a biologic agent, we review each patient's vaccination and exposure history. Ideally, this review should be performed before the start of immunosuppressive therapy, when the likelihood of developing a protective immune response to any needed vaccine is highest and when live vaccines can be given safely. (See <a class="local">'Pretreatment screening'</a> above and  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Approach to vaccination'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Contraindications – Contraindications to the use of anti-TNF therapies (briefly summarized) include (see <a class="local">'Contraindications'</a> above and  <a class="medical medical_review" href="/d/html/7790.html" rel="external">"Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'Use of TNF inhibitors'</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Active, uncontrolled infection</p><p class="bulletIndent3"><span class="glyph">-</span>Latent (untreated) tuberculosis</p><p class="bulletIndent3"><span class="glyph">-</span>Demyelinating disease (eg, multiple sclerosis, optic neuritis)</p><p class="bulletIndent3"><span class="glyph">-</span>Uncontrolled heart failure</p><p class="bulletIndent3"><span class="glyph">-</span>Malignancy</p><p></p><p class="bulletIndent2">The safety of anti-TNF therapies and risk of recurrent malignancy in patients with a history of malignancy is less well established than in patients without such a history; these issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitoring – In addition to clinical observation, monitoring the response to anti-TNF agents may include therapeutic drug monitoring (checking drug trough levels, anti-drug antibodies), biomarker levels (eg, fecal calprotectin, C-reactive protein), and colonoscopy with biopsies. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adverse events – Potential adverse events associated with TNF-alpha inhibitors include (see <a class="local">'Adverse events'</a> above and  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Infection</p><p class="bulletIndent3"><span class="glyph">-</span>Malignancy</p><p class="bulletIndent3"><span class="glyph">-</span>Induction of autoimmunity</p><p class="bulletIndent3"><span class="glyph">-</span>Demyelinating disease</p><p class="bulletIndent3"><span class="glyph">-</span>Heart failure</p><p class="bulletIndent3"><span class="glyph">-</span>Injection site reactions</p><p class="bulletIndent3"><span class="glyph">-</span>Infusion reactions</p><p class="bulletIndent3"><span class="glyph">-</span>Neutropenia</p><p class="bulletIndent3"><span class="glyph">-</span>Cutaneous reactions, including psoriasiform lesions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-integrin antibodies </strong>– For treating patients with moderately to severely active UC, <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a> is a recombinant humanized, monoclonal antibody, developed as a gut-selective anti-integrin specifically targeting alpha-4-beta-7 integrin in the gastrointestinal tract. Vedolizumab is not typically associated with systemic immunosuppression because it interferes with lymphocyte trafficking limited to the gastrointestinal tract. (See <a class="local">'Anti-integrin antibodies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Small molecules </strong>– For treating patients with moderately to severely active UC, <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> and <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a> are orally-administered Janus kinase inhibitors that decrease signaling by a number of cytokine and growth factor receptors. Potential adverse events associated with JAK inhibitors include herpes zoster infection and thromboembolism. (See <a class="local">'Small molecules'</a> above.)</p><p></p><p class="headingAnchor" id="H584110516"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Paul Rutgeerts, MD (deceased), who contributed as a section editor for UpToDate in Gastroenterology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Masuda H, Iwai S, Tanaka T, Hayakawa S. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995; 46:111.</a></li><li><a class="nounderline abstract_t">Abreu C, Sarmento A, Magro F. Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients. Dig Liver Dis 2017; 49:1289.</a></li><li><a class="nounderline abstract_t">Andrisani G, Armuzzi A, Marzo M, et al. What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? World J Gastrointest Pharmacol Ther 2016; 7:387.</a></li><li><a class="nounderline abstract_t">Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52:998.</a></li><li><a class="nounderline abstract_t">Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462.</a></li><li><a class="nounderline abstract_t">Taxonera C, Barreiro-de Acosta M, Calvo M, et al. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. Dig Dis Sci 2015; 60:3075.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142:257.</a></li><li><a class="nounderline abstract_t">D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106:199.</a></li><li><a class="nounderline abstract_t">Hindryckx P, Novak G, Vande Casteele N, et al. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther 2017; 45:617.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146:85.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146:96.</a></li><li><a class="nounderline abstract_t">Pugliese D, Felice C, Landi R, et al. Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug Healthc Patient Saf 2016; 8:1.</a></li><li><a class="nounderline abstract_t">Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology 2017; 153:827.</a></li><li><a class="nounderline abstract_t">Vande Casteele N, Herfarth H, Katz J, et al. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology 2017; 153:835.</a></li><li><a class="nounderline abstract_t">Chen DY, Chen YM, Hung WT, et al. Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment. Ann Rheum Dis 2015; 74:2261.</a></li><li><a class="nounderline abstract_t">Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol 2015; 110:1324.</a></li><li><a class="nounderline abstract_t">Stragier E, Van Assche G. The use of fecal calprotectin and lactoferrin in patients with IBD. Review. Acta Gastroenterol Belg 2013; 76:322.</a></li><li><a class="nounderline abstract_t">D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18:2218.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Panés J, Zhang H, et al. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. Gastroenterology 2016; 150:96.</a></li><li><a class="nounderline abstract_t">Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol 2015; 8:23.</a></li><li><a class="nounderline abstract_t">De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 2013; 19:2111.</a></li><li><a class="nounderline abstract_t">Mosli MH, Zou G, Garg SK, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2015; 110:802.</a></li><li><a class="nounderline abstract_t">Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383.</a></li><li><a class="nounderline abstract_t">Jürgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011; 9:421.</a></li><li><a class="nounderline abstract_t">Ljung T, Karlén P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53:849.</a></li><li><a class="nounderline abstract_t">Lau MS, Tsai HH. Review of vedolizumab for the treatment of ulcerative colitis. World J Gastrointest Pharmacol Ther 2016; 7:107.</a></li><li><a class="nounderline abstract_t">Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369:699.</a></li><li><a class="nounderline abstract_t">Feagan BG, Rubin DT, Danese S, et al. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol 2017; 15:229.</a></li><li><a class="nounderline abstract_t">Loftus EV Jr, Colombel JF, Feagan BG, et al. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis 2017; 11:400.</a></li><li><a class="nounderline abstract_t">Kirchgesner J, Desai RJ, Beaugerie L, et al. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2022; 20:314.</a></li><li><a class="nounderline abstract_t">Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017; 66:839.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367:616.</a></li><li><a class="nounderline abstract_t">Fernández-Clotet A, Castro-Poceiro J, Panés J. Tofacitinib for the treatment of ulcerative colitis. Expert Rev Clin Immunol 2018; 14:881.</a></li><li><a class="nounderline abstract_t">Sands BE, Taub PR, Armuzzi A, et al. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2020; 18:123.</a></li><li><a class="nounderline abstract_t">Makris A, Barkas F, Sfikakis PP, et al. The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-Analysis of Randomized Controlled Trials. J Clin Med 2022; 11.</a></li><li><a class="nounderline abstract_t">Sleutjes JAM, Roeters van Lennep JE, van der Woude CJ, de Vries AC. Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation. Inflamm Bowel Dis 2023; 29:531.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Panés J, D'Haens GR, et al. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol 2019; 17:1541.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Melmed GY, Vermeire S, et al. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis 2018; 24:2258.</a></li><li class="breakAll">https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and (Accessed on July 26, 2019).</li><li class="breakAll">Charles-Schoeman et al. MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. https://acrabstracts.org/abstract/mace-and-vte-across-upadacitinib-clinical-trial-programs-in-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis/ (Accessed on March 06, 2023).</li><li><a class="nounderline abstract_t">Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2017; 376:1723.</a></li><li><a class="nounderline abstract_t">Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet 2022; 399:2113.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology 2020; 158:2139.</a></li><li><a class="nounderline abstract_t">Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367:495.</a></li><li><a class="nounderline abstract_t">van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367:508.</a></li><li class="breakAll">Ozanimod [prescribing information]. Summit, NJ: Celgene Corporation; 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf (Accessed on November 11, 2022).</li><li><a class="nounderline abstract_t">Sandborn WJ, Feagan BG, D'Haens G, et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2021; 385:1280.</a></li></ol></div><div id="topicVersionRevision">Topic 4054 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8926619" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28986117" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27602239" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12801957" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16339095" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Infliximab for induction and maintenance therapy for ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26044830" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22062358" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21045814" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28074618" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Review article: dose optimisation of infliximab for acute severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23735746" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23770005" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26893582" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28780013" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28774547" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26443609" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26303131" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24261027" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The use of fecal calprotectin and lactoferrin in patients with IBD. Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22344983" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26376350" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25553077" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The role and utility of faecal markers in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23883959" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25964225" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393175" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Infliximab, azathioprine, or combination therapy for Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21334460" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15138212" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26855816" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Review of vedolizumab for the treatment of ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23964932" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Vedolizumab as induction and maintenance therapy for ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27639327" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27683800" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-term Efficacy of Vedolizumab for Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33387667" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26893500" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The safety of vedolizumab for ulcerative colitis and Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22894574" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30285500" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Tofacitinib for the treatment of ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31077827" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36498468" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35590447" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30476584" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29850873" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29850873" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29850873" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28467869" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35644166" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32092309" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22873530" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22873531" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22873531" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34587385" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
